Circadian clock suppression in cancer-related fatigue

癌症相关疲劳中的昼夜节律抑制

基本信息

批准号：
7595251
负责人：
MARY E HARRINGTON
金额：
$ 14.05万
依托单位：
SMITH COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-03-25 至 2011-02-28
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): Circadian or daily rhythms modulate physiological responses. Robust daily rhythms are predictive of improved prognosis for cancer patients, independent of performance status measures. Disruption of circadian rhythms is associated with poor sleep quality and negative mood, fatigue, and reduced quality of life. The ability to care for a patient at home is often lost when the patient no longer sleeps during the night. The mechanism by which tumors suppress circadian rhythms and impair quality of life is unknown. We hypothesize that cytokine release induced by tumors may act directly in the neural system driving circadian rhythms and this action may induce fatigue and circadian rhythm disruption. Previous studies have shown that central administration of the cytokines TGF-1 and neuregulin-1 and systemic administration of IFN-1 can disrupt behavioral rhythms in hamsters and mice. As an animal model of tumor-induced disruption, we will determine if peripheral administration of TGF-1 and neuregulin-1 can similarly disrupt locomotor activity rhythms in mice. We will determine if cytokines can suppress the rhythms expressed by isolated suprachiasmatic nucleus (SCN), immune system organs, thymus and spleen, and other tissues (lung and mammary gland). Further experiments will assess if erlotinib or gefitinib, blockers of epidermal growth factor receptor (EGFR) tyrosine kinase activation used for chemotherapy, can improve circadian rhythm regularity and amplitude following disruption by TGF-1. These experiments are designed to mimic clinical data showing such effects in patients. We will determine with animals the optimal timing for administration of erlotinib or gefitinib to maximize the potential benefit to the circadian system. This research will increase our understanding of the biological mechanism by which tumor growth can impact the circadian system. We will describe effects of circadian clock output suppression on immune system function and on rhythms endogenous to select organs. Our studies will clarify if such effects could be mediated by cytokines, if action is peripheral or central, and if clinical reports of improved quality of life following administration of specific cytokine receptor blockers might be attributable to improved circadian regularity. This research will apply directly to clinical use of EGFR blockers, by investigating a rationale for optimal timing of these compounds. Cancer patients often suffer from disrupted circadian rhythms resulting in poor sleep quality, negative mood, fatigue and reduced quality of life. Tumors induce cytokine release, which may be responsible for circadian disruption and subsequent fatigue. By blocking the action of cytokines with specific compounds, we hope to clarify the downstream effects of cytokines on the immune and circadian systems. Clinical reports of improved quality of life after administration of cytokine blockers might be attributable to improved circadian rhythms.

描述（由申请人提供）：昼夜节律或每日节奏调节生理反应。强大的每日节奏可预测癌症患者的预后改善，而与绩效状态无关。昼夜节律的破坏与睡眠质量差，情绪不良，疲劳和生活质量降低有关。当患者在夜间不再睡觉时，在家中照顾患者的能力通常会失去。肿瘤抑制昼夜节律和损害生活质量的机制尚不清楚。我们假设肿瘤诱导的细胞因子释放可能直接作用于驱动昼夜节律的神经系统中，并且这种作用可能诱导疲劳和昼夜节律破坏。先前的研究表明，细胞因子TGF-1和Neuregulin-1的中央给药以及IFN-1的全身给药会破坏仓鼠和小鼠的行为节奏。作为肿瘤诱导的动物模型，我们将确定TGF-1和Neuregulin-1的外围施用是否会类似地破坏小鼠的运动性运动节律。我们将确定细胞因子是否可以抑制由分离的上张核（SCN），免疫系统器官，胸腺和脾和其他组织（肺和乳腺）表达的节奏。进一步的实验将评估Erlotinib或Gefitinib（表皮生长因子受体（EGFR）的阻滞剂）是否用于化学疗法的酪氨酸激活激活，可以改善TGFF-1破坏后昼夜节律的定期和振幅。这些实验旨在模仿显示患者这种影响的临床数据。我们将与动物一起确定给药的最佳时机，以最大程度地利用昼夜节律系统的潜在益处。这项研究将增加我们对肿瘤生长会影响昼夜节律系统的生物学机制的理解。我们将描述昼夜节律抑制对免疫系统功能和选择器官内源性节奏的影响。我们的研究将澄清是否可以通过细胞因子，作用是周围或中心介导的，以及在给药特定的细胞因子受体阻滞剂后改善生活质量的临床报道可能归因于改善的昼夜节律规律性。这项研究将直接用于EGFR阻滞剂的临床使用，通过研究这些化合物的最佳时机的基本原理。癌症患者经常遭受昼夜节律破坏，导致睡眠质量不佳，情绪低下，疲劳和生活质量降低。肿瘤会诱导细胞因子释放，这可能导致昼夜节律破坏和随后的疲劳。通过阻止细胞因子用特定化合物的作用，我们希望阐明细胞因子对免疫和昼夜节律系统的下游影响。给药细胞因子阻滞剂后生活质量改善的临床报道可能归因于改善的昼夜节律。